◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksB › BLSM

BlossomHill Therapeutics, Inc. (BLSM) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-09-08

BlossomHill Therapeutics, Inc. (BLSM) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 63 employees. Its market capitalization is roughly $640 million. In the fiscal year ended 2025-12-31, BLSM reported $0M in revenue and ($61M) in net income.

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment.

Interactive charts & full statements →

BLSM Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-31
Total Revenue$0M$0M
Operating Income (EBIT)($64M)($36M)
Net Income($61M)($31M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BLSM Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-03-31
Total Revenue$0M$0M
Operating Income (EBIT)($22M)($12M)
Net Income($21M)($10M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BLSM Free Cash Flow History

BLSM Balance Sheet History

Balance sheet2025-12-312024-12-31
Total Assets$163M$107M
Total Liabilities$295M$180M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BLSM viewer.

Other Companies in Biotechnology

← BLSHAll “B” companiesBLSR →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.